Glioblastoma multiforme

Search with Google Search with Bing
Information
Disease name
Glioblastoma multiforme
Disease ID
Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT05023551 Active, not recruiting Early Phase 1 Study of DSP-0390 in Patients With Recurrent High-Grade Glioma September 8, 2021 July 31, 2024
NCT03911388 Active, not recruiting Phase 1 HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors September 12, 2019 September 1, 2026
NCT04900792 Active, not recruiting Phase 1 A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma February 28, 2023 December 31, 2025
NCT04195139 Active, not recruiting Phase 2 Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM February 22, 2018 December 31, 2025
NCT03961971 Active, not recruiting Phase 1 Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM February 18, 2020 September 2025
NCT04671459 Active, not recruiting Phase 2 TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine December 26, 2020 December 9, 2024
NCT02933736 Active, not recruiting Early Phase 1 Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients October 2016 January 2025
NCT02344355 Active, not recruiting Phase 2 A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme March 13, 2017 December 2027
NCT02441322 Active, not recruiting N/A Evaluating Therapeutic Response to Novo-TTF December 2014 December 2023
NCT04471844 Active, not recruiting N/A Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM December 8, 2020 August 2026
NCT02586857 Active, not recruiting Phase 1/Phase 2 A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM) January 25, 2016 December 31, 2025
NCT04250922 Active, not recruiting Phase 2/Phase 3 LAM561 With RT and TMZ for Adults With Glioblastoma December 1, 2019 May 30, 2025
NCT04295759 Active, not recruiting Phase 1 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas July 27, 2020 June 30, 2024
NCT02974738 Active, not recruiting Phase 1 A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) December 7, 2016 April 14, 2025
NCT03344250 Active, not recruiting Phase 1 Phase I EGFR BATs in Newly Diagnosed Glioblastoma March 1, 2018 December 8, 2024
NCT05222802 Active, not recruiting Phase 1 A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) February 25, 2022 September 30, 2025
NCT04726397 Active, not recruiting N/A UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: A Phase 2 Trial March 29, 2021 May 2024
NCT01752491 Active, not recruiting Phase 1 A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme April 1, 2013 December 31, 2024
NCT05608395 Active, not recruiting Phase 2 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET) May 1, 2020 December 31, 2024
NCT02715609 Active, not recruiting Phase 1/Phase 2 Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma June 15, 2016 September 2, 2024
NCT00555399 Active, not recruiting Phase 1/Phase 2 Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) November 28, 2007 November 20, 2024
NCT03389802 Active, not recruiting Phase 1 Phase I Study of APX005M in Pediatric CNS Tumors March 1, 2018 September 30, 2024
NCT05934630 Active, not recruiting Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors July 12, 2023 July 12, 2028
NCT02717962 Active, not recruiting Phase 2 Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting January 20, 2017 March 30, 2024
NCT03050736 Active, not recruiting Phase 2 Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression December 17, 2017 December 30, 2023
NCT03561207 Active, not recruiting 3D Prediction of Patient-Specific Response June 11, 2018 December 2024
NCT04606316 Active, not recruiting Phase 1 Surgical Nivolumab And Ipilimumab For Recurrent GBM February 1, 2021 December 31, 2024
NCT05190315 Active, not recruiting Phase 1 Chlorpromazine and Standard of Care in Glioblastoma January 28, 2022 July 2024
NCT02780024 Active, not recruiting Phase 2 Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM March 2015 February 28, 2026
NCT02781792 Active, not recruiting Phase 2 Temozolomide Chronotherapy for High Grade Glioma August 11, 2016 July 14, 2024
NCT03630289 Active, not recruiting N/A Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM July 27, 2018 December 31, 2023
NCT05432375 Active, not recruiting Early Phase 1 Study of Tinostamustine for Adjuvant Treatment of Glioblastoma July 1, 2022 November 30, 2024
NCT03665545 Active, not recruiting Phase 1/Phase 2 Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma October 25, 2018 December 31, 2023
NCT05551013 Available Treatment of Recurrent GBM With APG-157 Via Expanded Access
NCT02146066 Available Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
NCT06404034 Available Expanded Access to Gallium Maltolate (GaM)
NCT00751270 Completed Phase 1 Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas November 2005 January 2011
NCT00050986 Completed Phase 1/Phase 2 Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme December 2002 October 2008
NCT03712293 Completed N/A ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy August 28, 2018 December 31, 2023
NCT03722355 Completed Phase 3 Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma November 9, 1990 October 18, 2002
NCT00792012 Completed Phase 1 A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma November 2005 July 2016
NCT00800917 Completed Phase 2 A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme November 2008 February 2010
NCT00805961 Completed Phase 2 RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM January 2009 May 2013
NCT00817284 Completed Phase 2 Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM) November 2008 November 2011
NCT00879437 Completed Phase 2 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma September 1, 2009 October 2, 2017
NCT00892177 Completed Phase 2 Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme October 2009 July 1, 2019
NCT00892931 Completed Phase 2 Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme April 2009 September 2011
NCT00916409 Completed Phase 3 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) June 2009 March 2017
NCT00089427 Completed Phase 1 IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma July 2004
NCT00943007 Completed N/A Comparison of Standard Neuronavigation With Intraoperative Magnetic Resonance Imaging (MRI) for the Neurosurgical Treatment of Malignant Brain Tumors February 2010 December 2013
NCT00967330 Completed Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma June 2010 September 2014
NCT00968240 Completed Phase 1 Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) July 2009 January 2014
NCT00979017 Completed Phase 2 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme November 2009 January 2013
NCT00093964 Completed Phase 2 Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) October 13, 2004 October 21, 2010
NCT00995007 Completed Phase 2 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas September 2009 December 2015
NCT01006044 Completed Phase 2 Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection October 2009 August 2014
NCT00104091 Completed Phase 2 Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors December 2004 June 2007
NCT01071837 Completed Phase 2 APG101 in Glioblastoma December 2009 October 2014
NCT01081223 Completed Phase 1/Phase 2 Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma April 2010 March 2011
NCT01089868 Completed Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients January 2007 July 2012
NCT01091792 Completed Early Phase 1 Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM) March 2010 April 2, 2015
NCT00107003 Completed Phase 2 GW572016 to Treat Recurrent Malignant Brain Tumors March 30, 2005 November 30, 2012
NCT01112527 Completed Phase 2 PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma April 2010 September 2015
NCT01113398 Completed Phase 2 AMG 102 and Avastin for Recurrent Malignant Glioma August 2010 September 2015
NCT01115491 Completed Phase 2 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme June 2010 July 2012
NCT00024570 Completed Phase 1/Phase 2 Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma November 2000 July 2007
NCT01120639 Completed Phase 1/Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform April 2010 November 15, 2020
NCT01124461 Completed BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor January 2010 November 2017
NCT01435395 Completed Phase 1 Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme December 2011 April 2016
NCT00409214 Completed Phase 2 Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma November 2006
NCT00004688 Completed Phase 2 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms August 1996 July 1998
NCT02709226 Completed Phase 1 Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma June 15, 2016 July 19, 2023
NCT00412542 Completed Phase 2 Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas October 2003 October 2009
NCT02751138 Completed Determination of Immune Phenotype in Glioblastoma Patients March 1, 2016 January 1, 2023
NCT00430911 Completed Phase 3 Radiotherapy for Malignant Astrocytomas in the Elderly February 2001
NCT00441142 Completed Phase 1/Phase 2 Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors May 25, 2007 October 10, 2017
NCT02853565 Completed Phase 1 A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme August 2016 September 2018
NCT02858895 Completed Phase 2 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma April 11, 2017 October 31, 2019
NCT00024557 Completed Phase 1 Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients June 2001 July 2007
NCT00038493 Completed Phase 2 Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme September 21, 2001 August 1, 2005
NCT02898012 Completed Phase 2 Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status October 2010 June 2013
NCT02926222 Completed Phase 2 Regorafenib in Relapsed Glioblastoma November 2015 June 2021
NCT00590681 Completed Phase 2 Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme February 2007 September 2014
NCT02966509 Completed N/A Engagement of Patients With Advanced Cancer August 2013 December 2016
NCT00613093 Completed Phase 2 Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma October 2002 August 2008
NCT03027388 Completed Phase 2 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma January 9, 2019 August 31, 2022
NCT03072134 Completed Phase 1 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma April 24, 2017 July 1, 2021
NCT03075514 Completed N/A Ketogenic Diets as an Adjuvant Therapy in Glioblastoma April 1, 2017 March 5, 2019
NCT00041587 Completed Phase 1/Phase 2 Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma July 2002 July 2007
NCT00501891 Completed Phase 2 Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma July 2007 November 2009
NCT00064779 Completed Phase 1 Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma July 2003 July 2007
NCT00076986 Completed Phase 3 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme February 2004 March 2007
NCT00677716 Completed Phase 2 Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse July 2007 November 2011
NCT03276286 Completed N/A Nativis Voyager for Newly Diagnosed GBM November 10, 2017 May 31, 2022
NCT03291990 Completed Early Phase 1 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme October 18, 2017 August 19, 2020
NCT03310372 Completed Phase 2 Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme February 13, 2008 June 26, 2012
NCT00504660 Completed Phase 2 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients September 2003 August 2010
NCT00704080 Completed Phase 1 A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas August 2008 February 2013
NCT00509821 Completed Phase 2 Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma October 2007 March 2016
NCT00704288 Completed Phase 2 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme May 2008 December 2012
NCT00589875 Completed Phase 2 Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma March 2007 August 2016
NCT04610229 Completed N/A Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas. February 1, 2016 August 26, 2019
NCT03626896 Completed N/A Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients August 17, 2018 June 19, 2019
NCT00747253 Completed Phase 1 Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors August 2008 April 2010
NCT02189109 Completed Phase 1 The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma May 2014 April 2018
NCT02223052 Completed Phase 1 Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies October 27, 2014 December 18, 2018
NCT02286167 Completed N/A Glioma Modified Atkins-based Diet in Patients With Glioblastoma November 2014 July 12, 2019
NCT00031083 Completed Phase 1 Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas April 2, 2002 October 10, 2003
NCT02296580 Completed N/A A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) February 2014 September 30, 2021
NCT00544817 Completed Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme April 2007 August 2010
NCT02366728 Completed Phase 2 DC Migration Study for Newly-Diagnosed GBM October 12, 2015 October 31, 2020
NCT02378532 Completed Phase 1 The Addition of Chloroquine to Chemoradiation for Glioblastoma August 2016 July 30, 2019
NCT02386826 Completed Phase 1 INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme September 22, 2015 August 23, 2023
NCT00400322 Completed N/A Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection August 2006 June 2008
NCT02465268 Completed Phase 2 Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme August 9, 2016 November 30, 2023
NCT02498665 Completed Phase 1 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies November 2015 September 2018
NCT02502708 Completed Phase 1 Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors October 2015 February 28, 2020
NCT02507102 Completed N/A A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia August 2015 March 26, 2018
NCT00402116 Completed Phase 1/Phase 2 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients September 2006 December 2009
NCT05402241 Completed IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study October 21, 2021 November 15, 2023
NCT02550249 Completed Phase 2 Neoadjuvant Nivolumab in Glioblastoma June 2015 March 2017
NCT02590263 Completed Phase 1/Phase 2 Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma August 24, 2015 August 27, 2020
NCT02619864 Completed Phase 1 mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme December 22, 2016 February 25, 2020
NCT01135875 Completed Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients October 2009 April 2013
NCT01144247 Completed Phase 1 Cellular Immunotherapy Study for Brain Cancer July 2010 July 2015
NCT01151670 Completed Phase 1 Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors August 2010 August 2014
NCT01177397 Completed Phase 1/Phase 2 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma July 20, 2010 December 9, 2016
NCT01180816 Completed Phase 1 Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA August 2010 August 11, 2020
NCT04444427 Completed Phase 1/Phase 2 Evaluation of GLR2007 for Advanced Solid Tumors July 15, 2020 July 29, 2022
NCT00112502 Completed Phase 2 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme September 2005 September 2014
NCT01209442 Completed Phase 2 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme September 16, 2010 February 3, 2017
NCT01213407 Completed Phase 2 Dendritic Cell Cancer Vaccine for High-grade Glioma April 2010 November 2015
NCT01260506 Completed Phase 1/Phase 2 Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme December 2010 December 20, 2018
NCT01268566 Completed Phase 2 A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme January 2011 November 2012
NCT01269424 Completed Phase 1 BG & TMZ Therapy of Glioblastoma Multiforme November 22, 2011 September 26, 2022
NCT04790097 Completed N/A FET-PET Directed Simultaneous In-field Boost for Primary GBM February 21, 2017 December 30, 2020
NCT01280552 Completed Phase 2 A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) January 2011 December 2015
NCT00116376 Completed Phase 1/Phase 2 Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM) January 2004 November 2005
NCT01285414 Completed Phase 2 Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme December 2010 March 2012
NCT01290263 Completed Phase 1/Phase 2 Amgen 386 for Recurrent Glioblastoma December 2010 January 2017
NCT01290692 Completed Phase 2 Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma June 2011 February 2014
NCT01290939 Completed Phase 3 Bevacizumab and Lomustine for Recurrent GBM October 2011 April 2020
NCT01294735 Completed Phase 1 Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) February 2011 May 2012
NCT01301430 Completed Phase 1/Phase 2 Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. September 2011 May 2015
NCT01308684 Completed Phase 1 A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma May 2011 February 2013
NCT01316809 Completed Phase 1 AZD8055 for Adults With Recurrent Gliomas March 4, 2011 April 4, 2016
NCT04810182 Completed Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS September 10, 2020 December 31, 2023
NCT01349660 Completed Phase 1/Phase 2 Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme December 2011 December 29, 2018
NCT00154375 Completed Phase 3 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma October 2004
NCT01353625 Completed Phase 1 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. April 25, 2011 March 12, 2021
NCT03849105 Completed Phase 1/Phase 2 131I-IPA and Concurrent XRT in Recurrent GBM April 9, 2019 October 31, 2022
NCT01402063 Completed Phase 2 PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation September 2011 June 2015
NCT02654964 Completed Phase 1 Cancer Stem Cell High-Throughput Drug Screening Study December 2015 June 2023
NCT01450449 Completed Phase 3 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme February 2009 November 2014
NCT01468324 Completed Phase 1 AZD7451 for Recurrent Gliomas October 5, 2011 April 23, 2014
NCT01470794 Completed Phase 1 Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor February 2012 April 12, 2016
NCT01474239 Completed Phase 2 A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma November 2011 December 2013
NCT01475006 Completed Phase 1 AMG 595 First-in-Human in Recurrent Gliomas February 2012 April 2016
NCT01478178 Completed Phase 1/Phase 2 Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma October 2011 October 2016
NCT01478854 Completed N/A Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide December 27, 2011 April 25, 2018
NCT00179907 Completed Phase 1/Phase 2 A Phase I/II Study of the Photon Radiosurgery System May 2001 December 2013
NCT00187486 Completed Phase 2 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors August 2004 March 2011
NCT01540513 Completed N/A PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404 March 2012 October 2014
NCT01562197 Completed Phase 2 A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma April 2014 December 2018
NCT01564914 Completed Phase 2 A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma May 2012 June 2015
NCT04446416 Completed N/A Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients July 21, 2020 August 4, 2023
NCT00209989 Completed Phase 2 Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme October 2005 June 2011
NCT01588769 Completed Phase 1 A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients August 2011 April 2013
NCT01618747 Completed An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse March 15, 2013 December 24, 2015
NCT01631552 Completed Phase 1/Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer December 17, 2012 August 13, 2020
NCT00224978 Completed Phase 3 Chloroquine for Treatment of Glioblastoma Multiforme January 2005 August 2005
NCT01756352 Completed Phase 2 FET-PET for Evaluation of Response of Recurrent GBM to Avastin February 2013 September 13, 2015
NCT01800695 Completed Phase 1 Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme April 2, 2013 June 19, 2017
NCT01808820 Completed Phase 1 Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma August 21, 2013 July 16, 2022
NCT01811498 Completed Phase 1/Phase 2 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM February 2013 October 2021
NCT01811992 Completed Phase 1 Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma April 2014 January 2021
NCT01856933 Completed Phase 2 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) May 2013 February 2015
NCT01865162 Completed Phase 1 Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study January 2013 January 2021
NCT01873469 Completed Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme July 2013 October 2018
NCT00262730 Completed Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM January 2006 April 2010
NCT00267592 Completed Phase 2 Safety and Efficacy of Talampanel in Glioblastoma Multiforme December 2005 February 2011
NCT01929720 Completed N/A Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors August 2011 September 2014
NCT01931098 Completed Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab December 10, 2015 September 12, 2019
NCT03834740 Completed Early Phase 1 A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection December 21, 2018 February 18, 2022
NCT01956734 Completed Phase 1 Virus DNX2401 and Temozolomide in Recurrent Glioblastoma September 2013 March 2017
NCT01967758 Completed Phase 1 Phase I Study of Safety and Immunogenicity of ADU-623 January 8, 2014 August 15, 2018
NCT01985256 Completed Phase 1 Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor February 2014 March 3, 2016
NCT02006563 Completed Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors June 8, 2011 July 2017
NCT02010606 Completed Phase 1 Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma January 8, 2014 July 10, 2021
NCT02017249 Completed Phase 1 Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme March 2014 October 6, 2015
NCT02022384 Completed Immunophenotyping From Blood of Patients With Malignant Gliomas December 2013 December 31, 2022
NCT02026271 Completed Phase 1 A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma June 2015 August 2019
NCT02029573 Completed Phase 2 Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma January 1, 2014 December 31, 2016
NCT00301418 Completed Phase 1/Phase 2 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma March 2006 May 2014
NCT02049489 Completed Phase 1 A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma December 2013 March 2017
NCT02052648 Completed Phase 1/Phase 2 Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors March 2014 June 20, 2019
NCT02067156 Completed Phase 2 Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma February 2014 February 2017
NCT02078648 Completed Phase 1/Phase 2 Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme May 2014 January 22, 2018
NCT02104882 Completed Phase 1/Phase 2 INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study March 2014 September 2016
NCT02120287 Completed Phase 2 Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme May 2014 March 31, 2018
NCT00323115 Completed Phase 2 Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme May 2006 July 2013
NCT03170141 Enrolling by invitation Phase 1 Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme May 31, 2020 December 31, 2023
NCT05908669 Enrolling by invitation Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme August 25, 2023 December 31, 2026
NCT03311542 No longer available Expanded Access for Pembrolizumab (MK-3475)
NCT04321694 No longer available Expanded Access for KHK2455
NCT05917821 Not yet recruiting New Antigens Against Glioblastoma August 1, 2023 September 30, 2027
NCT04845919 Not yet recruiting Phase 2 Sonodynamic Therapy With ExAblate System in Glioblastoma Patients February 2023 November 2023
NCT06333899 Not yet recruiting Early Phase 1 Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion September 1, 2024 September 1, 2034
NCT05958485 Not yet recruiting A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research August 2024 August 2026
NCT04482933 Not yet recruiting Phase 2 HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma June 3, 2024 February 1, 2029
NCT05843253 Not yet recruiting Phase 2 Study of Ribociclib and Everolimus in HGG and DIPG May 30, 2024 May 30, 2034
NCT05839379 Not yet recruiting Targeted Pediatric High-Grade Glioma Therapy May 30, 2024 May 30, 2034
NCT06241391 Not yet recruiting N/A Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas February 2024 February 2025
NCT05095441 Not yet recruiting Phase 1 A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma March 15, 2023 April 30, 2026
NCT06329570 Not yet recruiting Phase 1/Phase 2 Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) July 1, 2024 March 31, 2027
NCT04373785 Not yet recruiting Phase 1/Phase 2 NG101m Adjuvant Therapy in Glioblastoma Patients January 1, 2024 December 31, 2027
NCT06353360 Not yet recruiting Phase 2 TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. April 5, 2024 March 9, 2026
NCT05756985 Not yet recruiting Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue June 2024 June 2028
NCT05500612 Not yet recruiting MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy June 2024 December 2025
NCT06218524 Not yet recruiting Phase 2 The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM December 1, 2024 July 31, 2028
NCT03866109 Recruiting Phase 1/Phase 2 A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT March 5, 2019 December 2024
NCT05353530 Recruiting Phase 1 Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) July 25, 2023 December 2042
NCT05328089 Recruiting Vacuolar ATPase and Drug Resistance of High Grade Gliomas January 30, 2020 April 2024
NCT04116411 Recruiting Phase 2 A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients September 4, 2019 August 31, 2024
NCT05303467 Recruiting Early Phase 1 A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM July 30, 2022 June 1, 2025
NCT05281731 Recruiting N/A Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma April 18, 2022 April 30, 2025
NCT05271240 Recruiting Phase 3 Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM April 27, 2022 April 1, 2028
NCT04478279 Recruiting Phase 1/Phase 2 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors July 1, 2020 December 2025
NCT04528680 Recruiting Phase 1/Phase 2 Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma October 29, 2020 September 2025
NCT04530006 Recruiting N/A Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma December 2, 2020 August 2025
NCT05182905 Recruiting Early Phase 1 AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients March 9, 2022 January 2025
NCT04614909 Recruiting Early Phase 1 Study of Pamiparib in Newly Diagnosed and rGBM January 11, 2021 December 2024
NCT04712721 Recruiting Early Phase 1 Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. October 14, 2021 June 26, 2024
NCT04752813 Recruiting Phase 2 A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) August 22, 2022 December 30, 2025
NCT04765098 Recruiting Phase 2 Tamoxifen Versus Etoposide After First Recurrence in GBM Patients January 28, 2022 December 2026
NCT04765514 Recruiting Phase 2 Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients July 27, 2022 June 2032
NCT05120284 Recruiting Phase 2 Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM) July 1, 2022 June 2025
NCT04780009 Recruiting Loupe-Based Intraoperative Fluorescence Imaging November 17, 2017 August 2024
NCT04825275 Recruiting Early Phase 1 Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial February 8, 2022 January 2025
NCT04869449 Recruiting Early Phase 1 Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas May 12, 2022 January 2025
NCT04977375 Recruiting Phase 1/Phase 2 Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma December 9, 2021 December 2026
NCT04978727 Recruiting Phase 1 A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma July 1, 2022 June 30, 2028
NCT05052957 Recruiting Phase 2 hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) January 20, 2023 December 1, 2024
NCT05084430 Recruiting Phase 1/Phase 2 Study of Pembrolizumab and M032 (NSC 733972) February 25, 2022 March 1, 2028
NCT05076513 Recruiting Early Phase 1 Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma October 29, 2021 February 2025
NCT05083754 Recruiting Phase 1 Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma August 31, 2022 January 2027
NCT06283927 Recruiting The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) January 1, 2023 January 1, 2028
NCT06271421 Recruiting N/A NanoTherm In Adjuvant Therapy of Glioblastoma Multiforme January 1, 2024 September 1, 2027
NCT06418113 Recruiting Phase 1 Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma March 21, 2024 March 21, 2027
NCT06157541 Recruiting Phase 1/Phase 2 T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma February 8, 2024 January 2028
NCT00083512 Recruiting Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme June 22, 2004
NCT06146738 Recruiting The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203) January 1, 2023 January 1, 2029
NCT06146725 Recruiting The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202) January 1, 2023 January 1, 2029
NCT06059690 Recruiting Phase 1/Phase 2 Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells September 6, 2023 September 30, 2028
NCT06054529 Recruiting Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients September 11, 2023 December 2025
NCT06039709 Recruiting Phase 1 Sonodynamic Therapy in Patients With Recurrent GBM January 31, 2024 June 2026
NCT06016452 Recruiting Phase 2 A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma November 13, 2023 November 2025
NCT06011109 Recruiting Phase 1/Phase 2 Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab December 13, 2023 January 31, 2025
NCT05979064 Recruiting N/A Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM) April 4, 2023 April 2027
NCT05977322 Recruiting Phase 1 A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. October 6, 2023 January 26, 2027
NCT01269853 Recruiting Phase 1/Phase 2 Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA October 2010 October 2026
NCT05956821 Recruiting Phase 1/Phase 2 Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age August 1, 2024 December 1, 2029
NCT05954858 Recruiting N/A Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma June 29, 2023 June 30, 2026
NCT06356883 Recruiting Phase 2 Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma July 2024 April 2028
NCT01837862 Recruiting Phase 1/Phase 2 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas October 22, 2013 April 2025
NCT02177578 Recruiting Phase 2 Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme July 8, 2014 December 2032
NCT02285959 Recruiting Phase 1 Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme June 2014 June 2025
NCT02331498 Recruiting Phase 1/Phase 2 Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme June 2015 August 2030
NCT06346821 Recruiting Tumor Treating Fields for Newly Diagnosed Glioblastoma: Two Emulated Trials With Chinese Multi-Hospital Based Real-World Data July 4, 2023 May 1, 2024
NCT05879367 Recruiting Phase 1 Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma July 24, 2023 December 15, 2024
NCT05864976 Recruiting Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning December 6, 2023 January 31, 2030
NCT02704858 Recruiting Phase 1/Phase 2 Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma April 8, 2016 December 2024
NCT05864534 Recruiting Phase 2 Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma January 31, 2024 August 2026
NCT05769660 Recruiting Phase 1 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination With Temozolomide in Patients With Recurrent or Progressive Glioblastoma Multiforme (GBM) November 29, 2022 October 31, 2024
NCT05708352 Recruiting Phase 2 A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment June 27, 2023 June 2029
NCT05686798 Recruiting Phase 1 Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. November 29, 2022 October 2024
NCT05624736 Recruiting Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning November 20, 2022 May 1, 2025
NCT03152318 Recruiting Phase 1 A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 July 18, 2017 December 2025
NCT03175224 Recruiting Phase 2 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors September 27, 2017 November 30, 2026
NCT05589961 Recruiting Early Phase 1 Safety and Efficacy of TRPP Therapy in Glioblastoma Multiforme October 2022 July 2024
NCT05565326 Recruiting Response Assessment During MR-guided Radiation Therapy for Glioblastoma September 1, 2022 December 31, 2024
NCT05563272 Recruiting Phase 2 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors June 6, 2023 December 29, 2025
NCT05561374 Recruiting Phase 1 Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma April 17, 2023 August 15, 2024
NCT06451042 Recruiting FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT) July 1, 2024 May 31, 2026
NCT03382977 Recruiting Phase 1/Phase 2 Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects December 6, 2017 August 2025
NCT05495295 Recruiting Phase 1 First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours July 18, 2022 July 31, 2027
NCT03582514 Recruiting Phase 1 PreOperative Brain Irradiation in Glioblastoma April 19, 2022 June 30, 2025
NCT03596086 Recruiting Phase 1/Phase 2 HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM December 11, 2017 December 30, 2025
NCT05450744 Recruiting Phase 1 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) April 1, 2023 June 2025
NCT03672721 Recruiting Phase 1/Phase 2 IA Carboplatin + Radiotherapy in Relapsing GBM July 10, 2018 June 10, 2026
NCT05423210 Recruiting Early Phase 1 Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme October 25, 2022 August 2026
NCT03861299 Recruiting N/A The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients. April 1, 2019 September 1, 2027
NCT03862430 Recruiting Phase 2 A Phase 2 Study of NanO2(TM) Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM March 31, 2023 September 30, 2025
NCT03865355 Recruiting Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients March 13, 2019 April 11, 2029
NCT05366179 Recruiting Phase 1 Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc September 2, 2022 May 2030
NCT02546102 Suspended Phase 3 Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma December 2024 December 2025
NCT01933815 Suspended Phase 1/Phase 2 Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma August 2013 May 2025
NCT01386710 Suspended Phase 1/Phase 2 Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma September 2011 December 2026
NCT04222309 Suspended Phase 1 Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) January 6, 2020 January 31, 2025
NCT00589095 Terminated Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities November 2006 August 2011
NCT00031538 Terminated Genetic Analysis of Brain Tumors March 1, 2002 April 29, 2015
NCT00062504 Terminated Phase 2 Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas July 2003 April 2006
NCT00376103 Terminated Phase 1/Phase 2 Radiation Boost for Newly Diagnosed Glioblastoma Multiforme August 2006
NCT00456612 Terminated Phase 1/Phase 2 Radiosurgery for Glioblastoma Multiforme February 2007 December 2010
NCT00473408 Terminated The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas March 2007 November 2011
NCT00479765 Terminated Phase 1/Phase 2 A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma March 2007 October 2009
NCT00508456 Terminated Phase 1 Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM August 2004 November 2008
NCT00515086 Terminated Phase 2 Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) August 2007 August 2009
NCT00548938 Terminated Phase 2 Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM October 2007 October 2010
NCT00615186 Terminated Phase 3 Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy June 2008 December 2013
NCT00650949 Terminated Phase 1/Phase 2 Efficacy Study of CYT997 in Combination With Carboplatin in Glioblastoma November 2009 June 2011
NCT00730262 Terminated Phase 2 Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme August 2008 June 2010
NCT00735436 Terminated Phase 2 A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM) December 2008 October 2012
NCT00923117 Terminated Phase 2 Sunitinib to Treat Recurrent Brain Cancer June 2008 June 2012
NCT00990496 Terminated Phase 1 A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) September 2009 October 28, 2010
NCT01044966 Terminated Phase 1/Phase 2 A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma September 2009 September 2014
NCT01110876 Terminated Phase 1/Phase 2 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) June 2011 July 2014
NCT01186406 Terminated Phase 2 Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM) April 2011 June 16, 2014
NCT01205334 Terminated Phase 1/Phase 2 Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme November 2010 March 2012
NCT01281982 Terminated (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas January 13, 2011 September 24, 2012
NCT01351519 Terminated Phase 2 A Study of Aminolevulinic Acid Used to Enhance Visualization and Surgical Removal of Brain Tumors May 2011 January 2015
NCT01508117 Terminated Phase 2 Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients August 2011 October 2012
NCT01526837 Terminated Phase 1 Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence October 2011 January 2012
NCT01587144 Terminated Phase 2 Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) June 19, 2012 April 15, 2013
NCT01666600 Terminated Phase 1/Phase 2 NOA-12: BIBF1120 and R-RT in Glioblastoma August 2012 September 2017
NCT01778530 Terminated Phase 2 TRC105 for Recurrent Glioblastoma December 2012 February 2014
NCT01884740 Terminated Phase 1/Phase 2 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 June 2013 October 2018
NCT01902771 Terminated Phase 1 Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors September 3, 2013 January 26, 2017
NCT02047214 Terminated Phase 2 Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy January 2014 December 2015
NCT02060955 Terminated Phase 2 Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan February 2014 July 2015
NCT02176720 Terminated Phase 1 Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma May 2014 March 2016
NCT02296476 Terminated Phase 2 A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) October 29, 2014 October 20, 2015
NCT02365662 Terminated Phase 1 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor January 9, 2015 March 15, 2018
NCT02414165 Terminated Phase 2/Phase 3 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma November 30, 2015 December 20, 2019
NCT02510950 Terminated Phase 1 Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma December 3, 2015 February 14, 2017
NCT02663271 Terminated Phase 2 TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma December 19, 2016 June 11, 2021
NCT02722512 Terminated Phase 1 Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine July 2016 November 13, 2019
NCT02769806 Terminated Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma May 23, 2016 June 21, 2019
NCT02850744 Terminated Phase 2 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients July 2015 November 2017
NCT02864368 Terminated Phase 1 Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens December 7, 2016 June 15, 2020
NCT02885324 Terminated Phase 2 Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children May 18, 2017 August 25, 2020
NCT03119064 Terminated Phase 1/Phase 2 BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma November 30, 2017 October 8, 2021
NCT03149575 Terminated Phase 3 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM October 27, 2017 August 31, 2019
NCT03332355 Terminated Phase 1 Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2 October 1, 2017 December 31, 2021
NCT03363659 Terminated Phase 2 Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme March 28, 2018 January 13, 2022
NCT03419403 Terminated Phase 3 UNITE Study: Understanding New Interventions With GBM ThErapy July 30, 2018 March 3, 2020
NCT03705351 Terminated Phase 1 Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM December 2, 2019 February 24, 2022
NCT03707457 Terminated Phase 1 Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma March 22, 2019 June 18, 2020
NCT03861598 Terminated Early Phase 1 Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells July 19, 2019 June 17, 2021
NCT04327011 Terminated Phase 1 A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 February 2011 December 2019
NCT04421378 Terminated Phase 1/Phase 2 A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma June 8, 2020 July 3, 2023
NCT04489420 Terminated Phase 1 Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM October 1, 2020 August 10, 2021
NCT04608812 Terminated Phase 1 Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection March 2, 2021 February 27, 2023
NCT00045968 Unknown status Phase 3 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer December 2006
NCT04874506 Unknown status Phase 2 MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) June 1, 2021 August 2023
NCT02772094 Unknown status Phase 2 Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas) May 2005 December 2016
NCT02663440 Unknown status Phase 2 Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme January 2016
NCT01923922 Unknown status N/A CT Perfusion in the Prognostication of Cerebral High Grade Glioma September 2013 December 2017
NCT01777919 Unknown status Phase 2 Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform January 2017 January 2020
NCT01567202 Unknown status Phase 2 Study of DC Vaccination Against Glioblastoma March 2012 February 1, 2021
NCT01317888 Unknown status N/A Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas January 2010
NCT01181193 Unknown status Phase 1/Phase 2 Vitamin D for Treatment of Glioblastoma Multiforme March 2011 March 2014
NCT01124539 Unknown status Phase 2 Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma December 2009 February 2015
NCT00768911 Unknown status Phase 1 CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme October 2008 June 2011
NCT00686387 Unknown status Establishment of a Brain and Spinal Tumor Tissue Bank May 2008 May 2013
NCT00683761 Unknown status Phase 1/Phase 2 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma August 2008 April 2010
NCT00635557 Unknown status Phase 1/Phase 2 Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme March 2008 August 2011
NCT00591058 Unknown status Phase 1 Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma February 2008 February 2010
NCT00535379 Unknown status Phase 2 SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme October 2007 January 2011
NCT00394628 Unknown status Phase 1/Phase 2 AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme October 2006
NCT00311857 Unknown status Phase 1/Phase 2 Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) February 2006
NCT00114309 Unknown status Phase 2 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma November 2004 August 2009
NCT05063682 Unknown status Phase 1 The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients May 15, 2020 October 2023
NCT04588454 Unknown status N/A 18F-PSMA PET/CT for Visualization of Glioblastoma Multiforme January 17, 2020 June 1, 2021
NCT04492163 Unknown status Phase 2 Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM July 14, 2020 January 2022
NCT04450160 Unknown status Phase 2 Trial of AEO in New Glioblastoma (GBM) December 2020 September 2022
NCT04284306 Unknown status Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM March 1, 2020 September 2022
NCT04277221 Unknown status Phase 3 ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM) September 19, 2019 December 31, 2022
NCT04224441 Unknown status Phase 2 Repurposing Chlorpromazine in the Treatment of Glioblastoma December 15, 2019 December 15, 2022
NCT03916757 Unknown status Phase 2 V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer April 16, 2019 June 15, 2020
NCT03896958 Unknown status The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) March 21, 2019 March 12, 2024
NCT05375318 Unknown status BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels March 1, 2021 July 1, 2022
NCT03780569 Unknown status N/A TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM April 27, 2017 January 2019
NCT03673787 Unknown status Phase 1/Phase 2 A Trial of Ipatasertib in Combination With Atezolizumab August 13, 2018 November 2023
NCT03642080 Unknown status MRI Predictors of Response to Tumor Treating Fields December 1, 2018 December 31, 2023
NCT03607643 Unknown status Phase 1/Phase 2 A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies January 15, 2019 December 15, 2020
NCT03401866 Unknown status N/A Multi-site Validation and Application of a Consensus DSC-MRI Protocol February 2018 July 2021
NCT03370926 Unknown status FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy October 31, 2016 October 31, 2019
NCT03347097 Unknown status Early Phase 1 Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme January 1, 2017 December 1, 2021
NCT03225963 Unknown status Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents. August 1, 2015 July 31, 2018
NCT03225300 Unknown status N/A Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation January 1, 2005 December 31, 2017
NCT03212235 Unknown status Phase 2 Hypofractionated Radiation Therapy for Glioblastoma June 5, 2017 June 1, 2020
NCT03025893 Unknown status Phase 2/Phase 3 A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme August 31, 2018 January 1, 2022
NCT02945826 Unknown status Phase 2 uPAR-PET/MRI in Glioblastoma Multiforme January 2017 December 2020
NCT02939378 Unknown status Phase 1/Phase 2 Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study October 2016 December 2018
NCT02937844 Unknown status Phase 1 Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme July 2016 July 2019
NCT02928575 Unknown status Phase 2 Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma August 2012 June 2017
NCT02844062 Unknown status Phase 1 Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme July 2016 July 2019
NCT02815410 Unknown status Phase 2 Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients July 2016 June 2022
NCT04776980 Withdrawn Early Phase 1 Multimodality MRI and Liquid Biopsy in GBM June 2022 June 22, 2022
NCT00943462 Withdrawn Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM June 2009 June 2011
NCT02540135 Withdrawn N/A Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma March 1, 2015 July 18, 2018
NCT05218408 Withdrawn Phase 1/Phase 2 CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type March 8, 2022 May 2024
NCT03235934 Withdrawn Glycemic Impact on Glioblastoma Outcomes December 1, 2018 January 24, 2020
NCT00904852 Withdrawn Phase 1 Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme June 2009 June 2010
NCT00797940 Withdrawn Phase 2 Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) January 2009
NCT01711580 Withdrawn Re-irradiation of High Grade Gliomas: a Quality of Life Study March 2013 September 2015
NCT03980249 Withdrawn Early Phase 1 Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells September 2020 June 2022
NCT00645385 Withdrawn Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme. June 2007 June 1, 2011
NCT00734864 Withdrawn Phase 1 Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma June 2009 June 2012
NCT01317212 Withdrawn Phase 1 Dose-Escalation Study of Carboplatin Administration Into the Brain for Glioblastoma Multiforme May 2015 May 2018
NCT00083447 Withdrawn Phase 3 Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme May 2004 June 2007
NCT01169415 Withdrawn N/A Effects of Steroid Tapering on Functional Capacity and Neurocognition June 2010 May 2014
NCT00243490 Withdrawn Phase 2 Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors January 2009
NCT01117155 Withdrawn A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas April 23, 2010 October 22, 2012
NCT03506139 Withdrawn Phase 2 Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma May 15, 2019 December 31, 2026
NCT00984438 Withdrawn Phase 1/Phase 2 Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme June 2009 June 2010
HPO alt_id (Human Phenotype Ontology)
HP:0100843
HPO Human Phenotype ID (Human Phenotype Ontology)
HP:0012174